1854-P: MiniMed 780G System Users with Spanish or English Language Settings Achieve Similar Glycemic Outcomes

Introduction and Objective: There are racial and ethnic disparities in diabetes technology adoption1 including the timing of technology initiation.2 The MinimedTM 780G (MM780G) system in the US is available in English and Spanish. We evaluated glycemia, insulin delivery, and system use in MM780G English (E) and Spanish (S) users. Methods: De-identified real-world data from US MM780G users of all ages who had ≥10 days of Carelink™ data uploaded between January 2023 and October 2025 were analyzed. Glycemic outcomes and insulin delivered were assessed in those with self-reported T1D and T2D with E and S language settings. System usage time was compared between languages in T1D and T2D using the two-sided Wilcoxon rank-sum test. Results: In both T1D and T2D users, E and S speakers met ADA recommended TIR, GMI and TBR goals. Bolus frequency and carb entry were similar between groups with fewer carb entries and grams of carbs entered by T2D users versus T1D users (Figure). Interestingly, S-speaking users had substantially fewer days of system use in T1D users (p<0.001) and in T2D users (p<0.001). Conclusion: US E- and S-speaking MM780G system users achieved similar glycemic outcomes, both exceeding ADA glycemic targets. S-speaking MM780G users had substantially less time on the system raising questions regarding equitable access to diabetes technology. Improved access to AID technology for S-speaking Americans may improve glycemic outcomes. Disclosure J. Cardin: Employee; Current; Medtronic. M. Liu: Employee; Current; Medtronic. F. Niu: Employee; Current; Medtronic. C. Rodriguez: Employee; Current; Medtronic. K.V. Tran: Employee; Current; Medtronic. J.J. Shin: Employee; Current; Medtronic. R. Vigersky: Employee; Current; Medtronic. J. McVean: Employee; Current; Medtronic.